Release Date: Friday, May 22, 2020
Expiration Date: Saturday, May 22, 2021


Educational Overview
The past decade has seen a growing diversity of bacterial resistance mechanisms and the global rise and spread of multidrug-resistant (MDR) pathogens. These infections pose a significant health threat and burden to individuals and healthcare institutions. In the US, the CDC estimates at least 2.8 million people acquire antimicrobial-resistant infections annually that result in at least 35,000 deaths. The diversity and spread of MDR and XDR (extensively drug-resistant) organisms challenge clinicians and substantially impact patient outcomes and healthcare costs. As a result, healthcare providers must be fully knowledgeable and remain up-to-date of the local epidemiology and resistance trends as well as recognize the latest tools available that aim to minimize the burden of these infections. These tools include rapid diagnostics and newer antimicrobials that can overcome resistance mechanisms and allow for pathogen-specific therapy. In this manner, clinicians have a greater ability to tailor management approaches based on patient factors and needs.

Learning Objectives
At the conclusion of the educational activity, the learner should be able to:

  • Summarize the changing epidemiology of antimicrobial resistance in relation to prevalence and resistance mechanisms
  • Differentiate the pharmacology and antibacterial activity of newer antimicrobial agents to combat antimicrobial-resistant infections
  • Identify strategies aimed to guide appropriate antimicrobial selection to optimize outcomes and reduce resistance development

Target Audience
This continuing medical education activity is planned to meet the needs of ID healthcare providers, including physicians, pharmacists, and microbiologists, in a variety of practice settings, including large and small health systems, outpatient clinics, managed-care organizations, long-term care facilities, and academia.




Robert A. Bonomo, MD, FIDSA

Professor of Medicine
Case Western Reserve University School of Medicine
Chief, Medical Service
Louis Stokes Cleveland Department of Veteran Affairs Medical Center
Northeast Ohio VA Health Care System
Cleveland, OH


Keith A. Rodvold, PharmD, FCCP, FIDSA

Professor, Department of Pharmacy Practice
Co-Director, Section of Infectious Diseases Pharmacotherapy
Professor of Pharmacy in Medicine
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL


Educational Format

This online presentation builds competence, confidence, and skills in the management of HABP/VABP while increasing the understanding of how to utilize the latest tools as part of antimicrobial stewardship efforts and interprofessional healthcare team. It is divided into 3 episodes.

Episode 1 – Keith A. Rodvold, PharmD
Introduction: Antimicrobial Resistance: What is the cost?

  • Review of clinical and economic burden of antimicrobial resistance

Episode 2 – Keith A. Rodvold, PharmD
Trends and Challenges with Antimicrobial-Resistant Bacteria

  • Trends in antimicrobial resistance prevalence: US and worldwide
  • Recognizing a growing diversity of resistance mechanisms
  • Role of local/unit-based antibiograms

Episode 3 – Robert A. Bonomo, MD
New Tools to Advance Pathogen-specific Therapy

  • Importance of timely, appropriate therapy on outcomes
  • Rapid diagnostics
  • Review of newer antimicrobials
  • Patient stratification for antimicrobial selection
  • Antimicrobial stewardship




This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Center designates this Enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.

Nurse Practitioners
Nurse Practitioners will receive certificate of AMA PRA Category 1 Credit™ as this is an ACCME accredited program and its accreditation is recognized by Nurse Practitioner boards.

AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 2.0 contact hours (0.20 CEUs) of continuing pharmacy education credits for participating in this activity.
ACPE UAN: 0473-9999-20-003-H01-P
Activity type: Knowledge-based

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CME/CPE information including target audience, learning objectives, and disclosures.
  2. Review the activity in its entirety.
  3. Complete the Online Post Test, Evaluation, and Credit Application form
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Pharmacists: The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit
  6. Physicians: Certificate of Credit will be emailed to you within 4 weeks.


Disclosure of Conflicts of Interest

In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.

Robert A. Bonomo, MD has relevant financial relationships with the following commercial interests:
Research Support: Wockhardt, VenatoRx, Entasis Therapeutics

Dr. Bonomo does not discuss off-label uses of any products.

Keith A. Rodvold, PharmD has relevant financial relationships with commercial interests:
Advisory Board: Entasis Therapeutics, Merck & Co., Inc., Nabriva Therapeutics, Qpex Biopharma, Shionogi

Consultant: BLC USA, Chimerix, Janssen Pharmaceuticals, Melinta Therapeutics, Paratek Pharmaceuticals, Shionogi, Spero Therapeutics, Venatorx Pharmaceuticals

Speaker’s Bureau: Merck & Co., Inc.

Dr. Rodvold does not discuss off-label uses of any products.

No (other) speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2020 Vemco MedEd. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support
This activity is supported by an educational grant from Merck & Co., Inc.


Start Activity

By clicking on the activity icon below, I acknowledge that I have read the entire CME/CPE information.